durvalumab,sorafenib,tremelimumab
astrazeneca,pfizer
['himalaya', 'hcc']
survival advantage seen with immune related adverse events in stride regimen on himalaya study for advanced hcc #asco23 
GI medical oncologist, Associate Prof Univ of WI, public health, proud Midwesterner, opinions mine  FCOI: https://t.co/vHScVEaG0b